Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and welcome to Intellia Therapeutics' third quarter 2025 financial results conference call. My name is Rocco, and I will be your conference operator today. Please be advised that today's conference is being recorded. I will now turn the conference over to Jason Fredette, Vice President of Investment Relations and Corporate Communications at Intellia. Please proceed, sir. Thank you, Rocco, and hello, everyone. Earlier this afternoon, we issued a press release and filed our 10-Q, outlining our recent business updates and our third quarter financial results. These documents can be found on the Investors and Media section of Intellia's website at intelliatx.com. At this time, I would like to take a moment to remind listeners that during this call, Intellia management may make certain forward-looking statements. We ask that you refer to our SEC filings, available at scc.gov for a discussion of potential risks and uncertainties. All information presented on this call is current as of today, and Intelia undertakes no duty to update this information unless required by law. Joining me on the call are John Leonard, our Chief Executive Officer, and Ed Dulac, our Chief Financial Officer. With that, I'll turn the call over to John. Thanks, Jason. And thanks to all of you who have tuned in for today's call. In terms of the agenda for today, we'll begin with the status of our NEXE program in ATTR amyloidosis, since that is obviously top of mind for all of you. We then will provide an update on the significant progress we have made with LanvoZ, which is being developed as a potential one-time treatment for patients with hereditary angioedema, or HAE. And we will close with Ed's financial review. First, for NEXE. Since the start of 2024, we've been enrolling patients in magnit...